Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Ryerson University

$25,000.00

Microfluidics-technology enabled double-emulsion system for thermal insulation of heat-sensitive medications

EF 2018-19

Résumé
We are working with the biotechnology company, VivaVax Inc., to develop a novel vaccine delivery model.*Currently, VivaVax is developing delivery solutions for the primary vaccines MMRII (Merck, United States)*and Gardasil 13 (Merck, United States), which are used globally to prevent infections of mumps, measles,*rubella, and human papillomavirus. The main innovation in VivaVax's vaccine delivery model is its ability to*maintain a near constant vaccine temperature while the external environmental temperature changes. VivaVax*achieves this by developing a proprietary thermal-protective formulation that is a mixture of amphiphilic*polymer constructs on poly-saccharide backbones, which have shown emulsion stability and biodegradability.*One of the company's challenges has been the large uncertainties in the consistency and quality of each*encapsulated vaccine package that is a result of the the traditional high pressure homogenization manufacturing*processes. For this NSERC Engage project, VivaVax will work with my research group to apply innovative*microfluidics technology to create multi-phasic encapsulations of the vaccines, within thin films of the*thermal-protective formulation, so that the vaccines can be protected in monodisperse and highly consistent*double emulsions.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
523895-2018
Name nom
Tsai, Scott
Department département
Mechanical and Industrial Engineering
Organization id
43
Institution établissement
Ryerson University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
2100
Research subject group en
Mechanical engineering
Research subject group fr
Génie mécanique
Research subject en
Mechanical engineering
Research subject fr
Génie mécanique
Partie
1
Nb partie
1
Application title
Microfluidics-technology enabled double-emulsion system for thermal insulation of heat-sensitive medications
Keyword
NSERC
Application summary
We are working with the biotechnology company, VivaVax Inc., to develop a novel vaccine delivery model.*Currently, VivaVax is developing delivery solutions for the primary vaccines MMRII (Merck, United States)*and Gardasil 13 (Merck, United States), which are used globally to prevent infections of mumps, measles,*rubella, and human papillomavirus. The main innovation in VivaVax's vaccine delivery model is its ability to*maintain a near constant vaccine temperature while the external environmental temperature changes. VivaVax*achieves this by developing a proprietary thermal-protective formulation that is a mixture of amphiphilic*polymer constructs on poly-saccharide backbones, which have shown emulsion stability and biodegradability.*One of the company's challenges has been the large uncertainties in the consistency and quality of each*encapsulated vaccine package that is a result of the the traditional high pressure homogenization manufacturing*processes. For this NSERC Engage project, VivaVax will work with my research group to apply innovative*microfluidics technology to create multi-phasic encapsulations of the vaccines, within thin films of the*thermal-protective formulation, so that the vaccines can be protected in monodisperse and highly consistent*double emulsions.